# A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

> **NCT01966471** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1846 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab Emtansine
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Paclitaxel
- **DRUG:** Epirubicin
- **DRUG:** Doxorubicin
- **DRUG:** Docetaxel
- **DRUG:** Cyclophosphamide
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT01966471
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-31
- **Primary completion:** 2019-11-27
- **Final completion:** 2021-06-04
- **Target enrollment:** 1846 (ACTUAL)
- **Last updated:** 2022-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01966471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01966471, "A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01966471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*